Association between mortality and glycaemic control (GC) in a large Swiss haemodialysis control

D. Creme¹, R. Winzeler², H. Räz³, D. Kiss⁷, T. Kistler⁴, A. Kneubühl⁵, M. Miozzari⁶, P. Ambühl²

¹ Royal London Hospital, London, ² Stadtspital Waid, Zürich, ³ Kantonsspital Baden, ⁵ Spital Lachen, ⁶ Kantonsspital Schaffhausen, ⁴ Kantonsspital Winterthur, ⁷ Kantonsspital Liestal

Background and Aims

Diabetes is the leading cause for end stage renal disease (ESRD) and initiation of renal replacement therapy (RRT) of which haemo-dialysis (HD) is most prevalent. The Dialysis Outcomes and Practice Patterns Study (DOPPS) as well as others have shown a clear link between poor glycaemic control (GC) and early mortality. There is scant information available in Swiss HD patients regarding prevalence outcomes for diabetic patients.

Methods and study design


- A prospective, dynamic, 3 year follow up study of HD-patients from 6 centres in Switzerland (*monitor!*-cohort).
- GC was assessed from HbA1c results that were then further adjusted for haemo-globin (Hb) and albumin (Alb) based on a formula by Hoshino et al. (2014).
- · Biochemical data was collected from routine annual reviews.
- To enable comparison with published data, GC was divided into 3 risk categories, increased risk with low HbA1c ≤5.9%, no risk with HbA1c 6.0-7.9%


Results

Table 1: General characteristics of the study population Diabetes No Diabetes **Variable** P Value n=207 n=358 <u>Demographic</u> 71 (61-78) 70 (56-78) Age (yrs) 0.157* Female sex % (n) 41 (84) 0.910** 40 (147) 0.003 Dialysis vintage (yrs) 3.6 (1.7-6.1) 2.8 (1.3-4.9) Charlson Score (adjusted for DM) 3.4 (±1.6) 3.3 (±1.6) 0.556 BMI (kg/m²) 26.8 (±6.5) 0.025 25.4 (±6.7) **Biochemistry** Haemoglobin (g/l) 0.017 114 (±13) 111 (±14) 0.194 Potassium (mmol/l) 4.9 (±0.8) 5.0 (±0.7) 0.020 Calcium (mmol/l) 2.24 (±0.20) 2.20 (±0.17) 0.956 Phosphate (mmol/l) 1.61 (±0.45) 1.61 (±0.43) Albumin (g/l) 38 (±4.4) 40 (±4.1) 0.000 CRP (mg/l) 3.5 (1-10) 5 (4-14) <0.001" 0.680* PTH (ng/l) 237 (153-401) 248 (114-438) 1.58 (±0.28) 1.68 (±0.33) 0.001 Kt/V

Out of 565 patients assessed 37% (2=207) had diabetes. Cox regression suggested a trend for presence of diabetes and mortality with HR 1.35 that was not significant (p=0.128; CI 95% 0.917-1.978). There was a trend in mortality with gender and diabetes with female HR 1.63 (CI 0.89-2.98) and male HR 1.20 (CI 0.72-2.01) which was not significant at p=0.11 and p=0.48, respectively. Within the diabetic cohort there was a trend for patients in the "at risk" hbA1c categories (<5.6% \rightarrow >7.9%) of HR 1.2 and 0.67 for original HbA1c results and HbA1c results adjusted for Hb/Alb respectively, which were not significant (p=0.576; CI 95% 0.659-2.120 and p=0.390; CI 95% 0.263-1.686).

Figure 1: Kaplan Meier plot: Survival according to stratification by a) Diabetes yes or no (all) b) Diabetes yes or no (female)





*Mann-Whitney test **Chi-squared test

HbA1c risk categories were not related to mortality either with original HbA1c or HbA1c adjusted for Alb and Hb in a Chi Square test. Analysis of gender split reveals an almost significant higher risk of mortality in females which is not present in the adjusted HbA1c model, p=0.055 vs. p=0.64 respectively.

Table 2: Incidence rates per 100 patient years with and without diabetes

Variable	Diabetes	No Diabetes	P-Value	95% CI
Death	14.7	10.3	0.070	0.95 - 2.10
Cardiovascular events	24.7	18.3	0.040	0.99 - 1.82
Hospital days	1397	963	<0.0001	1.40 - 1.51
Hospital Admissions	110	97	0.065	0.99 - 1.30
Length of stay	614	389	<0.0001	1.49 – 1.68

Summary and Conclusions


- Unlike many other countries who have found diabetes to be a clear mortality risk factor in HD patients, there was no significant association noted in this Swiss cohort
- Glycaemic control does not seem to be related to mortality risk
- The causational factors for the apparent lack of association between glycaemic control and mortality in this cohort warrant further investigation
- There is a trend in females for increased risk of mortality which warrants further investigation

Pharma Schweiz

• While mortality risk has not been shown to be significantly different, there is a higher incidence of cardiovascular events, number of days spent in hospital and length of stay for every admission













Fresenius Medical Care